Background
==========

Chronic atrial fibrillation (CAF) is an increasingly common cardiac disorder, with a prevalence of 0.9--1.2% in the population \[[@B1],[@B2]\], and it increases with age to 4.7% in persons aged 65 years or older \[[@B3]\]. It is associated with an annual incidence of thromboembolic stroke of 2--6% \[[@B4]\]. Oral anticoagulant drugs, i.e. vitamin K antagonists, have been shown in well-designed clinical trials to have antithrombotic efficacy in the prevention of embolic stroke in patients with CAF, and they are medically and economically justified \[[@B4],[@B5]\].

Warfarin is the standard anticoagulant drug used in Sweden. It is an efficacious anticoagulant, but it has a narrow therapeutic range. A prothrombin time corresponding to the International Normalized Ratio (INR) target of 2.5 (range 2--3) is recommended for most indications. The anticoagulant response to warfarin is influenced by many drug interactions and it is also affected by genetic and significant environmental variability. A large number of studies have demonstrated that the risk of bleeding complications during treatment with warfarin increases drastically with an INR above the target value, and that the antithrombotic effectiveness disappears with low INR values \[[@B6]-[@B8]\]. There is a relationship between the effectiveness of warfarin and the proportion of time within the therapeutic range, and such estimates have therefore been used as a measure of the quality of anticoagulation treatment \[[@B9]\]. Several studies indicate that CAF is the most common treatment diagnosis for warfarin \[[@B10],[@B11]\]. The treatment is considered fairly safe \[[@B12]\], although bleeding complications do occur \[[@B13]\]. The number of fatal or major bleeding complications in clinical practice is about 1.7% per patient-year \[[@B14]\]. Monitoring is frequently managed by general practitioners (GP) \[[@B15]\]. There is ongoing discussion concerning whether efficiency and safety can be kept as low in primary health care (PHC) as at special clinics for anticoagulation services.

The proportion of patients with CAF that are treated with warfarin in primary health care settings is increasing \[[@B2]\], but was shown in recent studies to vary widely, from 29--97% \[[@B2],[@B16]-[@B18]\]. A significant underuse of warfarin has been reported \[[@B3],[@B16],[@B19]\]. The proportion of CAF patients eligible for warfarin treatment varies from 41--61% depending on the criteria used \[[@B13],[@B20]\]. Contraindications for warfarin treatment have been reported in 11--18% of these patients \[[@B21],[@B22]\].

The literature indicates a variable level of anticoagulation intensity in real-life settings, with 43--81% of tests within the therapeutic range \[[@B23]-[@B26]\], and the proportion of time spent within the therapeutic range varying from 47--51% \[[@B22],[@B27]\]. Few studies have focused on monitoring in routine medical care, which is the predominant model of care in many countries.

Patients on warfarin treatment in Stockholm are now almost universally managed in PHC. Electronic patient records (EPR) are currently used by almost all GPs in the area, providing us with clinical data that is useful for research. The general objective of this study was to study the prevalence of CAF and its treatment with warfarin in everyday clinical practice in PHC in a representative sample of clinics. The specific objective was to assess prevalence, incidence, the proportion treated and the quality of anticoagulation control.

Methods
=======

Selection of PHC centres
------------------------

In order to compensate for local variations regarding the population, we invited one PHC centre from each of the five different health care districts in Stockholm County. The EPR included the entire medical record and no paper records were used. In each PHC centre one GP was appointed as investigator. The total registered population (calculated from a population registry maintained for each GP) of the participating GPs comprised 75 146 individuals at the end of the study period.

Identifying patients
--------------------

The initial selection criterion was all patients over 18 years of age with an encounter labelled \'Atrial fibrillation\' (code I48- in the Swedish primary care version of ICD-10), during a 12-month study period (June 1999 to May 2000). The diagnosis of CAF was based on a clinical diagnosis recorded by the GP, including persistent (i.e. en episode of atrial fibrillation that has not reverted spontaneously to sinus rhythm) and permanent atrial fibrillation (i.e. when attempts at restoration of sinus rhythm have failed or where the probability of successful cardio version is considered so low that no attempt is made) \[[@B28]\]. CAF is distinguished from \'Paroxysmal tachycardia\' (code I47-, including episodes of atrial fibrillation which are self-terminating) in the current classification. The second selection criterion was all patients on warfarin treatment. This was further specified as patients who were monitored with INR values *and*whose daily dosages of warfarin were ordered by a GP at the PHC centre.

Data collection
---------------

The EPR systems were searched for code I48-, INR, age and gender through their statistical modules for primary data retrieval. The investigator thereafter manually reviewed all EPRs including INR. Patients who had received a minimum of 30 consecutive days of treatment during the study period were included in the evaluation of proportion treated and the quality of anticoagulation control. We evaluated two groups of these patients, those with 1) established treatment, and those who 2) started treatment during the study period. For the first group, all patients with established warfarin treatment for CAF as the only treatment diagnosis, or one of several treatment diagnoses, were identified. The follow-up period for each of these patients was 12 months for two centres and three months for three centres, due to variable resources at the centres. The follow-up continued until the last day of the period or the date of discontinuation. For the second group, all patients were identified who started warfarin treatment for CAF as the only indication, or one of several indications, during the study period. The follow-up period was 90 days, starting with the first day of treatment. For both these groups we randomly selected (using a table of random numbers) five patients from each health care centre (a total of 25 patients per group), and they were subjected to a more detailed follow-up of INR monitoring. For the selected patients (as described above), information was collected concerning start date for treatment, and data from each monitoring episode (i.e. where PT was monitored *and*dosages given) including date and INR value. The monitoring of anticoagulant treatment was performed using INR, and the standard range was from 2.0 to 3.0 INR.

Statistical analysis
--------------------

The data were analysed using the SPSS^®^software programme. The time spent in the INR target range was estimated using linear interpolation \[[@B29]\], which assumes that the INR between two consecutive measurements varies linearly, including only INR values obtained at intervals of eight weeks or less. Independent two-sample t-tests were used to compare interval scaled variables. The Chi-square test was used to test the distribution of cross-classified nominal variables. Ninety-five percent confidence intervals (CI) were used.

Ethical considerations
----------------------

This study was approved by the regional ethics committee at Karolinska Institutet.

Results
=======

Occurrence and proportion treated
---------------------------------

The total registered population was 75 146. In total, 419 patients had CAF, giving a prevalence of 0.60% (age-adjusted 0.62%), and 50.1% were women (Table [1](#T1){ref-type="table"}). The age group 65 years or older accounted for 91.6% of patients with CAF, and 3.35% in the population. The prevalence of CAF increased with increasing age, from 0.19% in the age group 45--64 years, to 5.59% in the age group 85 years or older. Out of these, 211 patients were on warfarin treatment for CAF, from 20 to 76 patients at each PHC centre, 122 men and 89 women, and the mean age was 73.7 (CI 95% 72.4; 75.1) (Table [1](#T1){ref-type="table"}). Men were significantly predominant (P = 0.02), accounting for 57.8% (CI 95% 51.1; 64.4). The proportion treated with warfarin was 50.4%, declining from 85.7% in the age group 45--64 years, to 18.8% in the age group 85 years or older. The number of patients who started warfarin treatment for CAF at the participating PHC centres was 54, accounting for 25.6% of patients with CAF who were not on warfarin treatment, and for 0.07% of the population.

###### 

Registered population, prevalence of chronic atrial fibrillation (CAF), patients established on warfarin treatment, and proportion treated, at five primary health care centres.

  **Age group**                          **\<45**   **45--64**   **65--74**   **75--84**   **85+**   **Total**   **Women**
  --------------------------------- ---- ---------- ------------ ------------ ------------ --------- ----------- -----------
  Registered population             N    45294      18539        5125         4470         1718      75146       38851
  Diagnosed CAF (n = 419)           \%   \<0.01     0.19         2.19         3.94         5.59      0.60        0.54
  Age adjusted                                                                                       0.62        0.60
  Established treatment (n = 211)   \%   \<0.01     0.16         1.35         2.04         1.05      0.28        0.23
  Age adjusted                                                                                       0.28        0.25
  Proportion treated                \%   \-         85.7         61.6         51.7         18.8      50.4        42.2\*

\* Significantly more men (p = 0.02)

Anticoagulation control
-----------------------

Among the 25 randomly selected patients *established on warfarin*treatment, the median start year for the treatment was 1997. Indications for warfarin treatment besides CAF were found for five patients: prosthetic valve (three patients), deep venous thrombosis (one), and cardiac infarction (one). A total of 216 INR monitoring episodes were identified. INR monitoring was done on average 1.3 times per month. The individual range for INR values was 2.0 to 3.0 INR for 24 of the patients, while one patient had a lower range (1.7 to 2.5). The proportion of time within the therapeutic range was 70.2% (Table [2](#T2){ref-type="table"}), and the proportion of values within the therapeutic range was 71.5%. Values with a high bleeding risk (INR \> 6.0) were not found.

###### 

Proportion of patient time (95 % confidence intervals) within International Normalized Ratio (INR) ranges for randomly selected patients started on, and established on, warfarin treatment for chronic atrial fibrillation. The standard INR range is 2.0 to 3.0, but there were some individual ranges.

                              **Started on warfarin (N = 25)**   **Established on warfarin (N = 24)**                       
  --------------------------- ---------------------------------- -------------------------------------- ------------------- -------------------
  Super therapeutic (\>3.0)   17.0 (7.9--26.1)                   14.4 (6.6--22.2)                       9.9 (1.3--18.5)     18.8 (8.0--29.7)
  Therapeutic (2.0 -- 3.0)    54.2 (42.1--66.4)                  66.9 (54.3--79.7)                      75.4 (61.1--89.8)   70.2 (59.9--80.4)
  Sub therapeutic (\<2.0)     28.7 (15.8--41.5)                  18.6 (6.7--30.5)                       14.6 (2.3--27.0)    11.0 (4.2--17.8)

In the 25 randomly selected patients for whom *warfarin treatment was initiated*during the study period, no treatment diagnosis other than CAF was found. Data concerning a total of 281 PT monitoring episodes were collected (during the patients\' first three months of treatment). PT values were monitored on average 3.8 times per month. The individual range for INR values was 2.0 to 3.0 for 24 of the patients, while one had a lower range (1.6 to 2.5). The proportion of time within the therapeutic range was 54.2% and 75.4% the first and the third months of treatment, respectively (Table [2](#T2){ref-type="table"}). A value associated with a high bleeding risk (INR \> 6.0) was found in one episode.

Discussion
==========

In this study we investigated warfarin treatment for CAF in PHC with regard to occurrence and quality of anticoagulation control. We found that CAF was common among the elderly in primary health care. It appears to be under-diagnosed, and it may also be under-treated. The quality of anticoagulation control with warfarin may only be improved to a limited extent. It was feasible to study warfarin treatment for CAF by reusing information in electronic patient records, although retrieving INR values required a manual review.

The prevalence figures for CAF in our study (0.6%, and 3.4% in 65+) are lower than in the studies mentioned above (0.9--1.2%, and 4.7--5.9% in 65+) \[[@B1]-[@B3]\], especially in patients 75 years or older, where our figures are significantly lower. This suggests that there may be an under-diagnosis of CAF in our study, or a selection bias in the types of patients seen in PHC. Our figures represent the prevalence in PHC (e.g. patients who actually were seen in PHC and were treated for CAF) during the one-year study period, and therefore are most probably underestimates of the prevalence in the registered population. The relationship we found between prevalence and age is in accord with findings in similar studies \[[@B1]-[@B3],[@B20]\]. The prevalence of patients treated with warfarin for CAF has differed somewhat in studies done in recent years. Our figure corresponds well with findings from other Swedish studies ranging from 0.3--0.4% \[[@B10],[@B15]\], and from a Finnish study where the reported prevalence was 0.3% \[[@B23]\].

The proportion treated with warfarin (50.4%) in our study can be considered intermediate as compared with studies mentioned above (29--97%) \[[@B2],[@B16]-[@B18]\]. However, considering the proportion of CAF patients who are found eligible for warfarin treatment (41--61%) \[[@B3],[@B20]\] and, on the other hand, the proportion of patients with contraindications for warfarin (11--18%) \[[@B21],[@B22]\], our figures suggest a minor underuse. The declining use of warfarin with older age was somewhat more marked in our study compared to findings in similar studies \[[@B2],[@B16]\]. Numerous barriers to warfarin treatment still exist in clinical practice, even for eligible patients. These include practical, patient- physician- and healthcare system-related barriers \[[@B30]\], among which a major factor seems to be patients\' unwillingness to take warfarin \[[@B31]\]. Our figures may therefore approach what can be achieved in everyday clinical practice. However, the extent to which these figures can be improved is uncertain, since the number of eligible patients is not known in our study. Further improvements should probably include new approaches to CAF treatment such as screening, disease-management teams in PHC, and new strategies for patient education. These need to be supported by the implementation of guidelines, and by new incentives and a health care policy that solve the problem of an increased clinical workload. The number of patients on warfarin treatment and their frequent health care contacts in PHC, a mean of more than once a month in our study, point out a considerable workload related to warfarin treatment, and this has received little attention.

Regarding the INR values, the quality of anticoagulation control can be considered fairly high. The figures were somewhat lower when initiating treatment, as expected. Our figures on monitoring episodes within the therapeutic range (71.5%) are in line with or are higher than figures reported in recent studies \[[@B23]-[@B26]\]. The proportion of time spent in the therapeutic range (70.2%) is higher than the figures mentioned above (47--51%) \[[@B27],[@B22]\]. These figures may be improved further, as shown by the special anticoagulation clinics \[[@B7]\], but probably only to a very limited degree. This would requires a more organised approach to anticoagulant management including computer dosing systems and improved systems for follow-up \[[@B32]\].

The major limitations of this study are that it is rather small, the lack of clinical features regarding potential contraindications to anticoagulation, and the lack of information about the presence or absence of risk factors for stroke. An evaluation including the safety of warfarin treatment in PHC would require a longer observation time and a larger sample of patients than in this study. Further, the study was conducted locally, and although we tried to compensate for local variations, conclusions about PHC in general must be made with caution. There is no reason to believe that patients on warfarin treatment were missed, as all patients receiving treatment (as defined above) at the PHC centres are registered under INR values in the laboratory module of the record systems. The actual therapeutic range for the patient is an important factor, as it is sometimes individualised in clinical practice, and this was taken into consideration in our study. Most earlier studies are not based on PHC with a registered population, a representative sample of patients, and records from everyday clinical practice, which are the advantages of our study.

Conclusions
===========

CAF is common among the elderly in primary health care, and about half of these patients are treated with warfarin. It appears to be under-diagnosed, and may also be under-treated. About two thirds of the treatment time is spent within the therapeutic range, and a further improvement of the quality of anticoagulation control with warfarin treatment may therefore be hard to achieve. Given the frequent monitoring episodes, there is a considerable workload related to warfarin treatment for CAF, both for patients and for care providers.
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